An Australian pharmaceuticals manufacturer claims it can produce a broad-spectrum antiviral spray which is more than 99% effective against the Delta strain of coronavirus in laboratory studies.​

The product, which comes in the form of a nasal spray, is sold in India and Europe.

It is not approved for use by the Therapeutic Goods Administration in Australia.

Luke Grant spoke to CEO of Starpharma, Dr Jackie Fairley, the company which produces the product about its development and use.

She says Viraleze has been adopted in countries hit hard by virus cases, and should be considered for approval in Australia to help prevent further outbreaks.​

Click play below to listen to the interview.